Evidence map›Paper›PMID 37365655›Full record

ArticleBMC research notes2023

Leishmanicidal and immunomodulatory activities of the formononetin (a natural isoflavone) against Leishmania tropica.

Hossein Mahmoudvand, Amal Khudair Khalaf, Pouya Zareh Rajabi, Nooshin Karbasian, Javad Ghasemian Yadegari

Open access · goldAbstract read
In one paragraph

Article in BMC research notes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Formononetin: pharmacological properties and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  3. Article
  4. Frontiers in pharmacology · 2025
    Article
  5. Frontiers in parasitology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Hossein MahmoudvandRazi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
Amal Khudair KhalafDepartment of Microbiology, College of Medicine, University of Thiqar, Thiqar, Iraq.
Pouya Zareh RajabiStudent Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.
Nooshin KarbasianStudent Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.
Javad Ghasemian YadegariRazi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. jv.ghasemian@gmail.com.
Lorestan University of Medical Sciences · IRThi Qar University · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis work aimed to examine the leishmanicidal, cellular mechanisms and cytotoxicity effects of formononetin (FMN), a natural isoflavone, against Leishmania tropica. We used the MTT assay to determine the leishmanicidal effects of FMN against promastigotes and its cytotoxicity effects on J774-A1 macrophage cells. The Griess reaction assay and quantitative real-time PCR were used to determine the nitric oxide (NO) and the mRNA expression levels of IFN-γ and iNOS in infected J774-A1 macrophage cells.

resultsFMN significantly (P < 0.001) decreased the viability and number of promastigotes and amastigotes forms. The 50% inhibitory concentrations value for FMN and glucantime was 9.3 and 14.3 µM for promastigote and amastigote, respectively. We found that the macrophages exposed with FMN especially at concentrations of 1/2 IC

Indexed as

Antiprotozoal AgentsIsoflavonesLeishmania tropicaAnimalsMacrophagesRNA, MessengerAntiprotozoal AgentsformononetinIsoflavonesRNA, MessengerAmastigoteInfectivityLeishmaniasisNitric oxidePromastigote

Identifiers

PMID37365655
PMCPMC10294385
OpenAlexW4382048136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.